Anaplastic lymphoma kinase tyrosine kinase inhibitor‐induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database-Reference-Cited by-同舟云学术

Anaplastic lymphoma kinase tyrosine kinase inhibitor‐induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database

Published:2021-03-25 Issue:4 Volume:46 Page:1148-1154
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Zhou Ziye¹,Wang Chenxiang¹,Ying Lili²,Jin Mi¹,Zhang Fangfang¹,Shi Dawei¹^ORCID

Affiliation:

1. Department of pharmacy The First Affiliated Hospital of Wenzhou Medical University Wenzhou China

2. Department of pathology The First Affiliated Hospital of Wenzhou Medical University Wenzhou China

Funder

Natural Science Foundation of Zhejiang Province

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13404

Reference36 articles.

1. Cancer statistics, 2019

2. Future options for ALK-positive non-small cell lung cancer

3. The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC

4. ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

5. Prediction of Crizotinib-Midazolam Interaction Using the Simcyp Population-Based Simulator: Comparison of CYP3A Time-Dependent Inhibition between Human Liver Microsomes versus Hepatocytes

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between Anaplastic Lymphoma Kinase (ALK) Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study.;Oncology;2024-05-20

2. Integrating network pharmacology and drug side-effect data to explore mechanism of liver injury-induced by tyrosine kinase inhibitors;Computers in Biology and Medicine;2024-01

3. Cardiac arrhythmias associated with anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS);Expert Opinion on Drug Safety;2023-07-10

4. Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer;JCO Oncology Practice;2023-06

5. Lorlatinib as a treatment for ALK-positive lung cancer;Future Oncology;2022-08